X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11) 11
male (10) 10
aged (9) 9
female (8) 8
index medicus (8) 8
middle aged (7) 7
multiple myeloma (7) 7
multiple myeloma - drug therapy (7) 7
bortezomib (6) 6
adult (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
dexamethasone - administration & dosage (5) 5
hematology (5) 5
oligopeptides - administration & dosage (5) 5
analysis (4) 4
cancer (4) 4
dexamethasone (4) 4
kaplan-meier estimate (4) 4
recurrence (4) 4
aged, 80 and over (3) 3
bortezomib - administration & dosage (3) 3
care and treatment (3) 3
disease-free survival (3) 3
follow-up studies (3) 3
low-dose dexamethasone (3) 3
medicine, general & internal (3) 3
multiple myeloma - mortality (3) 3
patients (3) 3
risk factors (3) 3
survival (3) 3
survival rate (3) 3
thalidomide - administration & dosage (3) 3
thalidomide - analogs & derivatives (3) 3
treatment outcome (3) 3
abridged index medicus (2) 2
adolescent (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bone and bones – pathology (2) 2
bone density conservation agents - adverse effects (2) 2
bortezomib – therapeutic use (2) 2
carfilzomib (2) 2
chemotherapy (2) 2
clinical trials (2) 2
combination (2) 2
dexamethasone - adverse effects (2) 2
diphosphonates - adverse effects (2) 2
diseases (2) 2
dosage and administration (2) 2
interleukin-6 (2) 2
intravenous administration (2) 2
lenalidomide (2) 2
monoclonal antibodies (2) 2
multiple myeloma - pathology (2) 2
oligopeptides - adverse effects (2) 2
oncology (2) 2
plus dexamethasone (2) 2
prognosis (2) 2
radiotherapy (2) 2
relapse (2) 2
surgical operative procedures (2) 2
thrombocytopenia (2) 2
102 (1) 1
118072-93- 8 (1) 1
[sdv.mhep.hem]life sciences [q-bio]/human health and pathology/hematology (1) 1
abnormalities (1) 1
abo blood-group system - immunology (1) 1
abo system (1) 1
activation (1) 1
adverse effects (1) 1
age factors (1) 1
alfa-interferon (1) 1
anemia (1) 1
anemia - chemically induced (1) 1
anti-bacterial agents - therapeutic use (1) 1
anti-interleukin-6 monoclonal-antibody (1) 1
antibodies (1) 1
antibodies - blood (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - adverse effects (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibody specificity (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols (1) 1
article (1) 1
bisfosfonati – štetni učinci (1) 1
bisphosphonate-associated osteonecrosis of the jaw - pathology (1) 1
bisphosphonate-associated osteonecrosis of the jaw - therapy (1) 1
bisphosphonates (1) 1
bisphosphonates – adverse effects (1) 1
bisphosphonates, adverse effects (1) 1
blood (1) 1
blood group a (1) 1
blood group b (1) 1
blood groups (1) 1
bolesti čeljusti, kemijski uzrokovane (1) 1
bone and bones - pathology (1) 1
bone and bones, pathology (1) 1
bone density conservation agent (1) 1
bone density conservation agents - therapeutic use (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 1, pp. 27 - 38
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 2, pp. 142 - 152
Journal Article
American Journal of Hematology, ISSN 0361-8609, 01/2015, Volume 90, Issue 1, pp. 42 - 49
Journal Article
Journal Article
British Journal of Haematology, ISSN 0007-1048, 05/2017, Volume 177, Issue 3, pp. 404 - 413
Journal Article
Journal Article
Haematologica, ISSN 0390-6078, 07/2019, p. haematol.2019.219295
Here, we are reporting the outcome of 226 myeloma patients presenting with extramedullary plasmacytoma or paraosseous involvement in a retrospective study... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1844 - 1844
Abstract Introduction: Carfilzomib is a selective proteasome inhibitor that is approved in the United States and other countries for the treatment of relapsed... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 30 - 30
Abstract Introduction: Single-agent carfilzomib has previously shown activity in patients with relapsed and refractory multiple myeloma (MM) who have high-risk... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 729 - 729
Abstract Introduction: The randomized phase 3 ENDEAVOR study (NCT01568866; N=929) demonstrated that carfilzomib and dexamethasone (Kd) significantly improved... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 4250 - 4250
Abstract Introduction: The ENDEAVOR study found that Kd was superior to Vd, with a 2-fold improvement in median PFS (18.7 vs 9.4 mo; HR=0.53; 95% CI,... 
Journal Article